Addex Pharmaceuticals said its CNS business director, Emmanuel le Poul, has left the company to pursue other opportunities and will not be replaced in the short term.
In addition, Addex’s metabolic disorders business unit and its inflammation business unit will be merged as an ongoing streamlining of the company.
Addex’s chief executive, Vincent Mutel, will take responsibility for the CNS business unit while Laurent Galibert will head to the combined two other units. Dr Galibert previously was head of the inflammation unit.
The Geneva-based company had to terminate in late 2009 its lead product for migraine (and also for gastroesophageal reflux disease) because of adverse side-effects. A post mortem indicated that failure resulted from the molecule’s chemical structure and not from the company’s technology platform, which is based on allosteric modulation or the specific way in which a candidate drug binds to a protein.
Copyright 2010 Evernow Publishing Ltd